According to newly published research, a new form of double therapy combining a traditional chemotherapy agent with targeted therapy could benefit patients with glioblastoma multiforme, although thus far studies have only been performed in vitro (on lab mice and on cells).
The treatment, investigated by researchers from the University of Massachusetts Medical School, involves the most commonly used chemotherapy drug, temozolomide, in combination with a targeted treatment, in this case a so-called Notch inhibitor.
A Notch inhibitor is a drug that inhibits or blocks the Notch signaling pathway, a pathway believed to be over-expressed in both glioma tissue as well as tumor cells.
CANCER TYPE(S)
Glioblastoma (brain cancer)
TREATMENT TYPE(S)
Combination chemotherapy and a targeted therapy
WHERE WAS THIS RESEARCH PUBLISHED?
Cancer Research
By Ross Bonander
Source
EurekAlert
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
